December 8, 2015
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President & Chief Executive Officer

Onconova to Present Results from Phase 2 Study of Oral Rigosertibin Combination with Azacitidine for MDS and AML PatientsTOKYO, Japan, December 8, 2015 --- SymBio Pharmaceuticals Limited (Headquarters:Tokyo, “SymBio”) announced today that its U.S. partner, Onconova Therapeutics, Inc.
(Headquarters: Newtown, PA, “Onconova”) has presented the results of its clinical trialfor oral rigosertib in combination with azacitidine for the treatment of front-line andsecond-line higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid
leukemia (AML), referred to as the 09-08 trial, at the 57th ASH Meeting. According toOnconova, combination results were positive, achieving a 77% overall response rate.
For more details on this press release, please visit Onconova’s homepage at
http://investor.onconova.com/releases.cfm
SymBio has already started the Phase 1 clinical trial in Japan for oral rigosertib (SyBC-1101, oral formulation) combined with azacitidine in HR-MDS patients (“Phase ICombination Trial”) in December 2015 and upon completion of this Phase 1 Combination
Trial, SymBio will consider participating in a global Phase 3 trial which Onconova plans
to initiate.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Myelodysplastic Syndromes (MDS)MDS patients often require frequent blood transfusions due to the development of severe
anemia (decrease in number of red blood cells), with a high rate of progression to AML.
There are an estimated 11,000 MDS patients in Japan alone, with the number of cases
expected to increase as the population ages. MDS and AML are widely recognized as blooddisorders that are difficult to manage given the limited therapeutic options available forpatients, particularly for patients who have a drug-resistant form of the disease. A highunmet medical need clearly exists for the establishment of new effective therapies to treat
both lower-risk MDS and HR-MDS.
About Azacitidine (Vidaza: currently marketed by Nippon Shinyaku Co., Ltd.)
Vidaza was approved in 2011, showing overall survival in the Phase 3 trial for the firsttime, and is currently used by MDS patients having difficulties in hematopoietic stem celltransplantation.
About Onconova Therapeutics, Inc.
Onconova Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on
discovering and developing novel products to treat cancer. Onconova's clinical andpre-clinical stage drug development candidates are derived from its extensive chemical
library and are designed to work against specific cellular pathways that are important incancer cells, while causing minimal damage to normal cells. In addition to rigosertib,
Onconova's most advanced drug candidate under development, two other drug candidates
are in clinical trials and several other compounds in the pre-clinical stage of development.
For more information, please visit http://www.onconova.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida
who previously served concurrently as Corporate VP of Amgen Inc. and founding
President of Amgen Japan. The company’s underlying corporate mission is to “deliver
hope to patients in need” as it aspires to be a leading specialty pharmaceutical companyin Asia Pacific dedicated to addressing underserved medical needs with main therapeutic
focus on oncology, hematology and pain management.

2